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O B J E C T I V E S The aim of this study was to characterize and evaluate the clinical impact of
untreated atherosclerotic disease after percutaneous coronary intervention (PCI) in patients with acute
coronary syndromes (ACS).
B A C KG ROUND Residual atherosclerotic disease after successful PCI may predispose future major
adverse cardiovascular events (MACE). Compared with intravascular ultrasound (IVUS), angiography
underestimates the presence and severity of coronary artery disease.
METHOD S Following successful PCI of all clinically significant lesions in 697 patients with ACS,
3-vessel grayscale and radiofrequency IVUS was performed. Lesions were prospectively characterized,
and patients were followed for a median of 3.4 years. A total of 3,229 untreated lesions (4.89  1.98
lesions/patient) were identified by IVUS, with mean plaque burden (PB) of 49.6  4.2%.
R E S U L T S By angiography these nonculprit lesions were mild, with mean diameter stenosis of 38.9 
15.3%. At least 1 lesion with a PB 70% (PB70 lesion) was found in 220 (33%) patients. By multivariable
analysis, a history of prior PCI and angiographic 3-vessel disease were independent predictors of PB70 lesions.
Patients with PB70 lesions had greater total percent plaque volume, normalized PB, fibroatheromas, thin-cap
fibroatheromas, and normalized volumes of necrotic core and dense calcium. Patients with PB70 lesions had
greater 3-year rates of MACE due to untreated nonculprit lesions (20.8% vs. 7.7%, p  0.0001). Among imaged
nonculprit lesions, the proportion of PB70 lesions causing MACE was significantly greater than non-PB70 lesions
(8.7% vs. 1.0%, p  0.0001).
CONC L U S I O N S After successful PCI of all angiographically significant lesions, overall untreated
atherosclerotic burden remains high, and PB70 lesions are frequently present in the proximal and
mid-coronary tree. Patients with PB70 lesions have greater atherosclerosis throughout the coronary tree,
have more thin-cap fibroatheromas, and are at increased risk for future cardiovascular events.
(PROSPECT: An Imaging Study in Patients With Unstable Atherosclerotic Lesions; NCT00180466) (J Am
Coll Cardiol Img 2012;5:S76–85) © 2012 by the American College of Cardiology Foundation
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S77n patients presenting with acute myocardial infarc-
tion or unstable angina with high-risk features,
revascularization with percutaneous coronary in-
tervention (PCI) results in improved long-term
survival and reduced future major adverse cardio-
vascular events (MACE) (1,2). However, despite
successful revascularization and implementation
of secondary prevention strategies, MACE still
occurs in approximately one-quarter of patients
with acute coronary syndromes (ACS) within 2 to
3 years (3).
See page S106
In asymptomatic patients, estimation of overall
plaque burden (PB) by coronary calcium scoring is
a significant predictor of future MACE and mor-
tality (4,5). However, the prognostic impact of
untreated lesions with high PB following ACS is
not fully understood. While coronary angiography
remains the predominant imaging modality used to
guide revascularization and treatment decisions in
ACS, it does not characterize the PB and compo-
sition of atherosclerotic plaque (6–9). Intravascular
ultrasound (IVUS) imaging provides more detailed
information regarding the extent and nature of
coronary atherosclerosis, including plaque area, ves-
sel remodeling, lesion length, presence of diffuse
plaque, and plaque morphology (8,9). Additional
characterization of the arterial wall in atheroscle-
rotic plaques can be derived from analysis of the
spectral (frequency) backscatter from IVUS (radio-
frequency IVUS), which has been correlated to
human histologic samples with high sensitivity and
specificity (10). The principal results from the
PROSPECT (Providing Regional Observations
to Study Predictors of Events in the Coronary Tree)
study, a multicenter, prospective, natural history
study of atherosclerosis in which patients with ACS
treated successfully with PCI underwent multimo-
dality coronary imaging, have been previously de-
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S78Imaging analysis. All baseline angiograms and
IVUS images were prospectively analyzed at inde-
pendent core laboratories without knowledge of
subsequent events. Angiographic qualitative and
quantitative measures (quantitative coronary an-
giography) of the entire length of the coronary tree
were made as previously described (11), including
each major epicardial coronary artery and every side
branch 1.5 mm in diameter.
Grayscale and IVUS-VH analysis were per-
formed in the core laboratory analyzing segmental
qualitative assessment and quantitative data output.
External elastic membrane (EEM) and lumen bor-
ders were contoured. Quantitative IVUS measure-
ments, including EEM cross-sectional area (CSA),
lumen CSA, plaque and media (EEM minus lu-
men) CSA, PB (plaque and media divided by EEM
CSA) for all recorded frames (each0.4 to 0.5 mm
in length), and minimal lumen area (MLA) were
Table 1. Characteristics of Patients With and Without PB70 Lesi
P
P
Age, yrs 58
Male 80
Diabetes mellitus 20
White 94
Height, cm 173
Weight, kg 83
Body mass index, kg/m2 27
Prior MI 12
Known CAD, stenosis 50% 17
History of prior PCI 15
Hypertension 53
Hypercholesterolemia 51
Current tobacco use 46
Clinical presentation
Recent STEMI (24 h) 30
NSTEMI 65
Unstable angina 3
Estimated creatinine clearance, ml/min 95
Fasting glucose, mg/dl 102
HbA1c 5
Metabolic syndrome 53
More than 1 culprit vessel 30
HS-CRP 6.5
Number of diseased epicardial coronary arteries*
1 20
2 42
3 37
Number of angiographic lesions/patient† 3.0
Values are median (interquartile range) or % (n/N). *Defined as a vessel with an
angiographic diameter stenosis 30%.
CAD  coronary artery disease; HS-CRP  high-sensitivity C-reactive proteinfarction; PB70  plaque burden 70%; PCI  percutaneous coronary interventioidentified per lesion. Volumetric data were calcu-
lated using Simpson’s rule and expressed normal-
ized to the length of imaged vessel or lesion.
Lesion analysis. Because physicians reviewing an-
iograms typically consider discrete mild or inter-
ediate lesions for treatment, we pre-specified
esions visually estimated as having an angiographic
ercent diameter stenosis (DS) 30% for further
valuation. By IVUS analysis, a lesion was defined
s a segment with 3 consecutive frames with
40% PB. By IVUS-VH analysis, lesion phenotype
as color-coded and classified as: 1) thin-cap fibro-
theroma–virtual histology (TCFA-VH); 2) thick-
ap fibroatheroma; 3) pathological intimal thicken-
ng; 4) fibrotic plaque; and 5) fibrocalcific plaque
sing criteria previously described, and reported as
SA and percentages of total plaque area (10).
ach grayscale and IVUS-VH frame was coregis-
ered to the angiographic roadmap using fiduciary
nts With
Lesions
Patients Without
PB70 Lesions p Value
1.3–68.1) 58.1 (50.5–66.2) 0.24
77/220) 75.2 (331/440) 0.13
5/220) 15.6 (68/437) 0.12
47/156) 92.5 (296/320) 0.49
68.0–178.0) 173.0 (165.1–179.0) 0.54
4.4–94.0) 83.0 (73.0–95.3) 0.82
5.4–30.8) 28.1 (25.0–31.4) 0.93
7/366) 7.9 (23/290) 0.04
8/212) 11.0 (48/437) 0.01
3/219) 8.6 (38/440) 0.01
15/217) 43.5 (190/437) 0.02
06/207) 41.6 (164/394) 0.02
00/217) 48.6 (211/434) 0.54
7/220) 29.8 (131/440) 0.86
45/220) 66.4 (292/440) 0.91
/220) 3.9 (17/440) 0.89
8.0–120.7) 100.3 (76.2–126.9) 0.34
0.0–121.0) 100.0 (90.0–114.0) 0.26
.4, 6.2) 5.7 (5.3–6.1) 0.14
15/215) 45.6 (193/423) 0.06
8/220) 28.0 (123/439) 0.44
.50–17.00) 8.10 (2.40–19.40) 0.30
4/219) 28.7 (123/428) 0.02
2/219) 44.4 (190/428) 0.56
3/219) 26.9 (115/428) 0.004
.50–5.00) 2.00 (1.00–3.00) 0.0001
ion with a visible angiographic diameter stenosis 30%. †Lesions with a visible
I  myocardial infarction; NSTEMI  non–ST-segment elevation myocardialons
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S79branch points to align the imaging modality
outputs.
Data, endpoints, and definitions. The primary end-
point of the PROSPECT study was MACE, de-
fined as the composite of cardiac death, cardiac
arrest, myocardial infarction, or unstable or progres-
sive angina requiring rehospitalization. On the basis
of follow-up angiography, MACE were adjudicated
as occurring at the initially treated lesion site(s)
responsible for the original ACS (the index “culprit”
lesions), or at previously untreated coronary seg-
ments (“nonculprit” lesions). Events occurring in
patients without follow-up angiography were
termed “indeterminate” in location. Events were
adjudicated by an independent committee blinded
to treatment allocation.
Statistical analysis. Categorical variables were sum-
marized using percentages and counts and com-
pared using chi-square tests or Fisher exact test
where appropriate. Continuous variables were sum-
marized as median with interquartile range or mean 
1 SD and compared using the nonparametric Wilcoxon
rank sum test. From those variables in Table 1, the
independent predictors of lesions with PB 70%
(PB70 lesions) were determined using stepwise
logistic regression with entry/stay criteria of 0.1/0.1.
Event rates were estimated by Kaplan-Meier meth-
ods and were compared using log-rank tests. The
unadjusted hazard ratios for MACE in patients
with versus without PB70 lesions were deter-
mined from a Cox proportional hazards model. A
p value 0.05 was considered statistically signif-
icant. All statistical analyses were performed
using SAS version 9.2 (SAS Institute Inc., Cary,
North Carolina).
R E S U L T S
A total of 697 patients with ACS were enrolled at
37 sites in the United States and Europe following
successful PCI of all culprit and angiographically
significant lesions. The median age was 58.1 years,
24.0% were women, and 17.1% had diabetes mel-
litus. Median follow-up was 3.4 years. As previously
reported, adherence of patients to prescribed dual
antiplatelet therapy, lipid-lowering medications,
and beta-blockers was high throughout the
follow-up period (11).
Overall disease burden. Angiographic multivessel
coronary artery was present in 74.2% of patients,
and 30.6% had 3-vessel disease. A mean of 207.1
67.5 mm of the coronary tree was analyzed by
IVUS in 660 patients. IVUS imaging identified3,229 lesions (mean 4.89  1.98 lesions/patient)
in the proximal-mid coronary tree. The mean PB
was 49.6  4.2%; 288 (8.9%) of the IVUS lesions
were PB70 lesions. By angiography these lesions
were mild, with mean DS 38.9  15.3%. By
IVUS-VH, a total of 1,736 fibroatheromas (mean
2.85  1.91 per patient), including 639 TCFA-VH
(mean 1.05  1.37 per patient) and 1,097 thick-cap
fibroatheromas (mean 1.79  1.48 per patient), were
identified. In the entire cohort, the proportion of
total plaque characterized as necrotic core and dense
calcium was 13.1% and 6.6%, respectively, while
59.1% was fibrotic tissue and 21.2% was fibrofatty.
Patients with PB70 lesions. At least 1 PB70 lesion
as present in 220 patients (33.0%). PB70 lesions
ere mild by quantitative coronary angiography
mean DS 39.2  14.8%). Characteristics of
atients with versus without PB70 lesions are
ummarized in Table 1. By multivariable analysis,
history of prior PCI and angiographic 3-vessel
isease were independent predictors of the occur-
ence of 1 PB70 lesion by IVUS; metabolic
syndrome was a borderline predictor (Table 2).
By grayscale IVUS analysis, patients with PB70
lesions had a greater number of IVUS lesions,
and were more likely to have at least 1 echolucent
plaque or ruptured plaque (Table 3). Overall
disease burden was greater in patients with PB70
lesions, as measured by overall percentage plaque
volume and normalized PB. By IVUS-VH anal-
ysis, patients with PB70 lesions had more fibro-
atheromas, more TCFA-VH, and greater nor-
malized volumes of necrotic core and dense
calcium. Even after excluding the individual
PB70 lesions from the analysis, the overall per-
centage PB, and normalized volumes of necrotic
core and dense calcium, remained significantly
greater in patients with compared with those
without PB70 lesions (Table 4).
Clinical outcomes. Table 5 summarizes the clinical
utcomes in patients with and without PB70 lesions
t 3-year follow-up. Overall MACE and MACE
Table 2. Independent Predictors of Lesions With
Plaque Burden >70%
Variable OR (95% CI) p Value
History of PCI 1.79 (1.07–2.99) 0.03
3-vessel disease* 1.77 (1.24–2.52) 0.002
Metabolic syndrome 1.35 (0.96–1.88) 0.08
*Defined as the presence of a lesion with visual angiographic diameter
stenosis 30% in all 3 major epicardial coronary vessels.
CI  confidence interval; OR  odds ratio; PCI  percutaneous coronary
intervention.
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S80arising from nonculprit lesions were greater in
patients with PB70 lesions, primarily due to in-
creased rates of revascularization and rehospitaliza-
tion for increasing angina (Fig. 1). Patients with
only 1 PB70 lesion had similar 3-year MACE rates
Table 3. Grayscale and IVUS-VH Findings in Patients With Versu
Patients
PB70 Les
Imaged nonculprit segments, mm 169.52 (136.76
IVUS lesions/patient 5.33 1.82
1 echolucent plaque 29.5 (65/22
1 plaque rupture 21.4 (47/22
Total nonculprit lesion length, mm 91.87 (69.20–
Total plaque volume, % 52.1 (49.7–5
Mean EEM CSA, mm3/mm 16.08 (13.88–
Mean lumen CSA, mm3/mm 7.44 (6.54–8
Mean plaque  media CSA, mm3/mm 8.41 (7.10–1
1 lesion with MLA 4.0 mm2 76.8 (169/2
TCFA-VH lesions/patient 1.24 1.42
ThCFA lesions/patient 2.04 1.49
Fibroatheromas/patient 3.28 1.89
PIT lesions/patient 1.61 1.72
Fibrocalcific lesions/patient 0.06 0.27
Patients with 1 TCFA 61.4 (124/2
Mean necrotic core CSA, mm3/mm 0.66 (0.39–1
Mean dense calcium CSA, mm3/mm 0.28 (0.15–0
Mean fibrous tissue CSA, mm3/mm 2.90 (2.21–3
Mean fibrofatty CSA, mm3/mm 0.89 (0.62–1
Necrotic core volume, % 14.1 (8.7–18
Dense calcium volume, % 5.9 (3.3–9.
Fibrous tissue volume, % 59.6 (55.3–6
Fibrofatty volume, % 18.4 (13.6–2
Values are median (interquartile range), mean  SD (n), or % (n/N).
CSA  cross-sectional area; EEM  external elastic membrane; IVUS-VH  intra
burden 70%; PIT  pathologic intimal thickening; TCFA-VH  thin-cap fibroa
Table 4. Grayscale and IVUS-VH Findings in Patients With Versu
Patients
PB70 les
Total plaque volume, % 48.3 (44.9–
Mean EEM CSA, mm3/mm 15.08 (11.29
Mean lumen CSA, mm3/mm 7.69 (5.75–
Mean plaque  media CSA, mm3/mm 7.24 (5.46–
Mean necrotic core CSA, mm3/mm 0.42 (0.21–
Mean dense calcium CSA, mm3/mm 0.18 (0.07–
Mean fibrous tissue CSA, mm3/mm 2.21 (1.45–
Mean fibrofatty CSA, mm3/mm 0.70 (0.36–
% Necrotic core volume 12.0 (6.4–1
% Dense calcium volume 4.9 (2.0–9
% Fibrous tissue volume 59.8 (53.8–
% Fibrofatty volume 18.3 (11.9–
Values are median (interquartile range).
IVUS-VH  intravascular ultrasound–virtual histology; other abbreviations as in Tacompared with patients with 2 PB70 lesions
(26.7% vs. 29.7%, p  0.68). In the overall cohort,
06 nonculprit lesions were responsible for clin-
cal events during the follow-up period. Of the 54
onculprit MACE-related lesions in which base-
ithout PB70 Lesions
Patients Without
PB70 Lesions p Value
1.04) 174.00 (132.45–216.61) 0.76
0) 4.67 2.03 (440) 0.0001
10.2 (45/440) 0.0001
10.5 (46/440) 0.0001
.01) 60.66 (37.24–93.04) 0.0001
47.9 (45.8–50.1) 0.0001
9) 16.13 (13.86–18.49) 0.83
8.35 (7.08–9.62) 0.0001
) 7.78 (6.56–8.99) 0.0001
44.8 (197/440) 0.0001
2) 0.96 1.34 (407) 0.005
2) 1.67 1.45 (407) 0.002
2) 2.63 1.89 (407) 0.0001
2) 1.76 1.69 (407) 0.17
2) 0.05 0.23 (407) 0.50
50.1 (204/407) 0.009
0.46 (0.26–0.69) 0.0001
0.19 (0.10–0.35) 0.0001
2.40 (1.81–3.05) 0.0001
0.82 (0.50–1.20) 0.03
11.6 (7.0–17.1) 0.003
4.7 (2.5–8.6) 0.006
59.9 (55.1–64.4) 0.32
20.9 (15.3–27.4) 0.01
ular ultrasound-virtual histology; MLA  minimum lumen area; PB70  plaque
oma-virtual histology; ThCFA  thick-cap fibroatheroma.
ithout PB70 Lesions, Excluding the Lesions With PB70
h
s
Patients without
PB70 lesions p Value
) 46.6 (43.5–50.3) 0.0001
.01) 15.47 (11.84–19.86) 0.02
) 8.02 (6.21–10.60) 0.0001
) 7.26 (5.44–9.39) 0.72
) 0.36 (0.18–0.68) 0.002
) 0.14 (0.05–0.31) 0.0004
) 2.23 (1.39–3.25) 0.44
) 0.73 (0.34–1.30) 0.83
10.9 (5.4–17.6) 0.004
4.0 (1.7–8.3) 0.002
) 60.6 (54.1–66.1) 0.05
) 19.5 (12.4–28.6) 0.04s W
With
ions
–21
(22
0)
0)
121
5.1)
18.7
.92)
0.10
20)
(20
(20
(20
(20
(20
02)
.00)
.49)
.65)
.38)
.2)
5)
2.7)
5.1)
vascs W
wit
ion
52.0
–19
9.83
9.36
0.77
0.38
3.42
1.28
9.3)
.5)
65.4
27.1ble 3.
ACE
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S81line IVUS imaging data were available, 25 (46%)
were PB70 lesions, and the proportion of PB70
lesions causing subsequent MACE was signifi-
cantly greater than the proportion of non-PB70
lesions responsible for MACE (8.7% vs. 1.0%,
p  0.0001).
Table 5. Three-Year Clinical Outcomes of Patients With Versus W
Patients With
PB70 Lesions
Composite MACE 29.1 (60)
Death 2.4 (5)
Cardiac death 1.9 (4)
Cardiac arrest 1.0 (2)
Myocardial infarction 4.5 (9)
Rehospitalization 26.5 (54)
For unstable angina 11.0 (22)
For progressive angina 23.6 (48)
Revascularization 26.0 (53)
Stent thrombosis (ARC definite/probable) 4.3 (9)
Nonculprit lesion–related MACE 20.8 (42)
Death 0.0 (0)
Cardiac arrest 0.0 (0)
Myocardial infarction 1.6 (3)
Rehospitalization 19.3 (39)
For unstable angina 3.5 (7)
For progressive angina 17.8 (36)
Revascularization 18.8 (38)
Values are % (n).
ARC Academic Research Consortium; CI confidence interval; HR hazard ratio; M
Figure 1. MACE During Follow-Up
Major adverse cardiac events (MACE) in patients with lesions with p
PB 70%. CI  confidence interval; HR  hazard ratio.Correlates and influence of the degree of plaque burden.
To further characterize the features and prognostic
impact of individual lesions according to PB, we
grouped the 3,229 nonculprit lesions prospectively
identified by IVUS into 4 groups according to their
maximum percent PB; those with maximum PB
out PB70 Lesions
Patients Without
PB70 Lesions HR (95% CI) p Value
16.7 (68) 1.87 (1.32–2.65) 0.0003
3.7 (15) 0.66 (0.24–1.82) 0.42
1.5 (6) 1.33 (0.38–4.71) 0.66
0.2 (1) 3.99 (0.36–43.99) 0.22
3.0 (12) 1.50 (0.63–3.55) 0.36
14.0 (57) 2.00 (1.38–2.91) 0.0002
6.9 (28) 1.57 (0.90–2.74) 0.11
10.6 (43) 2.38 (1.58–3.59) 0.0001
13.8 (56) 1.99 (1.37–2.90) 0.0002
2.5 (10) 1.80 (0.73–4.44) 0.19
7.7 (31) 2.85 (1.79–4.53) 0.0001
0.0 (0) N/A N/A
0.0 (0) N/A N/A
0.8 (3) 1.96 (0.40–9.73) 0.40
7.2 (29) 2.81 (1.74–4.54) 0.0001
3.5 (14) 0.98 (0.40–2.44) 0.97
4.2 (17) 4.49 (2.52–7.99) 0.0001
7.2 (29) 2.74 (1.69–4.44) 0.0001
major adverse cardiac events; N/A not applicable; PB70 plaque burden70%.
e burden (PB) 70% compared with those without lesions withithlaqu
fibroatheroma-virtual histo
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S8250% (median average PB over the nonculprit
lesion 42.9%, n  904), maximum PB of 50% to
60% (median average PB 47.5%, n  1,239),
maximum PB of 60% to 70% (median average PB
52.3%, n 798), and maximum PB70% (median
average PB 57.4%, n  288). Lesions with greater
maximum PB were significantly longer, had greater
total plaque volume, smaller MLA, were more
likely echolucent and/or ruptured plaques, had
greater amounts of necrotic core, and were more
likely to be fibroatheromas (Table 6). As seen in
Figure 2, the per-lesion event rate during the
median 3.4-year follow-up period increased expo-
nentially with increasing maximum PB.
D I S C U S S I O N
The PROSPECT study is the first prospective,
natural history study of atherosclerosis using mul-
timodality intracoronary imaging to characterize
d IVUS-VH Findings in 3,229 Individual Lesions According to the
PB <50%
(n  904)
PB 50%–60%
(n  1,239)
and volumetric data
6.01 (3.52–10.95) 10.87 (6.05–18.55
m3 90.87 (48.38–172.29) 159.87 (83.95–313
ia volume, mm3 38.74 (20.83–73.66) 76.08 (39.50–150
e, % 42.9 (41.3–44.7) 47.5 (45.3–49.9)
3/mm 15.62 (11.20–19.91) 15.12 (11.41–19.8
m3/mm 8.81 (6.43–11.34) 7.84 (5.89–10.50
ia CSA, mm3/mm 6.64 (4.81–8.56) 7.17 (5.46–9.37)
7.57 (5.48–10.05) 6.14 (4.39–8.23)
46.0 (43.6–48.1) 54.8 (52.4–57.4)
0.3 (3/904) 2.0 (25/1,239)
0.2 (2/904) 2.3 (28/1,239)
0.94 (0.86–0.98) 0.93 (0.84–1.00)
ta, %
volume 9.9 (5.0–16.1) 11.4 (5.7–18.5)
volume 3.4 (1.1–7.2) 4.2 (1.8–8.5)
volume 61.4 (54.3–67.0) 60.6 (54.2–65.9)
me 20.5 (13.0–30.1) 18.7 (11.9–28.1)
43.0 (348/810) 58.7 (656/1117)
15.7 (127/810) 20.1 (224/1117)
27.3 (221/810) 38.7 (432/1117)
52.1 (422/810) 37.3 (417/1117)
3.3 (27/810) 3.0 (34/1117)
1.6 (13/810) 0.9 (10/1117)
artile range) or % (n/N).
area; EEM  external elastic membrane; MLA  minimum lumen area; PB70
logy; ThCFA  thick-cap fibroatheroma.the coronary tree following high-risk ACS (11). In
this analysis, IVUS imaging demonstrated that
despite treating all lesions believed to be angio-
graphically significant with PCI, the overall re-
maining untreated atherosclerotic burden was
significant, with an average of nearly 5 lesions per
patient identified in the proximal mid coronary
tree alone. Mean plaque volume of these lesions
was nearly 50% of the EEM volume, with a
significant proportion of the plaque characterized
by IVUS-VH as necrotic core or dense calcium.
At least 1 PB70 lesion was found in one-third of all
patients. On a per-lesion basis, lesions with greater
PB also had other numerous high-risk characteris-
tics, including longer length and smaller MLA,
were more likely to contain angiographically
silent greater plaque ruptures, and had greater
amounts of necrotic core. Patients with a history
of prior PCI or visible angiographic lesions in all
3 coronary vessels, factors reflecting more exten-
ximum Severity of PB
PB 60%–70%
(n  798)
PB >70%
(n  288)
p Value
Trend
16.73 (9.72–28.81) 26.98 (17.26–39.62) 0.0001
251.94 (136.86–454.61) 450.46 (258.48–692.57) 0.0001
133.45 (71.32–238.67) 261.32 (149.28–394.08) 0.0001
52.3 (49.6–55.1) 57.4 (53.4–60.7) 0.0001
15.54 (12.29–19.01) 16.53 (13.51–20.42) 0.0004
7.33 (5.81–9.07) 6.95 (5.88–8.70) 0.0001
8.18 (6.27–10.25) 9.51 (7.40–11.96) 0.0001
5.01 (3.91–6.28) 4.14 (3.32–5.05) 0.0001
64.1 (62.1–66.6) 73.2 (71.2–75.4) 0.0001
6.6 (53/798) 18.1 (52/288) 0.0001
4.6 (37/798) 13.2 (38/288) 0.0001
0.93 (0.83–1.01) 0.96 (0.85–1.07) 0.0001
13.0 (7.3–20.1) 13.6 (8.5–20.2) 0.0001
5.6 (2.4–9.9) 6.0 (2.9–10.0) 0.0001
59.1 (53.6–64.4) 59.2 (53.6–64.4) 0.0001
18.1 (11.9–26.6) 17.5 (11.4–24.9) 0.0002
74.1 (519/700) 83.0 (210/253) 0.0001
30.9 (216/700) 29.6 (75/253) 0.0001
43.3 (303/700) 53.4 (135/253) 0.0001
23.4 (164/700) 15.4 (39/253) 0.0001
1.1 (8/700) 1.2 (3/253) 0.01
1.3 (9/700) 0.4 (1/253) 0.32
plaque burden; PIT  pathologic intimal thickening; TCFA-VH  thin-capTable 6. Grayscale an Ma
Grayscale lesion length
Lesion length, mm )
Total EEM volume, m .52)
Total plaque  med .00)
Mean plaque volum
Mean EEM CSA, mm 6)
Mean lumen CSA, m )
Mean plaque  med
MLA site data
MLA, mm2
Plaque burden, %
MLA site data
Echolucent plaque
Plaque rupture
Remodeling index
Volumetric IVUS-VH da
Mean necrotic core
Mean dense calcium
Mean fibrous tissue
Mean fibrofatty volu
VH lesion classification
Fibroatheroma
Thin cap
Thick cap
PIT
Fibrotic
Fibrocalcific
Values are median (interqu
CSA  cross sectional 
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S83sive coronary artery disease, were more likely to
have PB70 lesions. Patients with compared with
those without PB70 lesions had greater overall
atherosclerosis and necrotic core, both in the
PB70 lesions themselves and at other sites in the
coronary tree.
On a per-lesion level, the MACE rate during
median follow-up of 3.4 years rose exponentially
with increasing PB. On a patient level, patients
with PB70 lesions had nearly a 2-fold increase in
3-year MACE compared with patients without
PB70 lesions, primarily driven by increased rates of
rehospitalization and revascularization events aris-
ing from nonculprit lesions. More than two-thirds
of future clinical events in patients with PB70
lesions arose from nonculprit lesions, compared
with less than one-half of the events in patients
without a PB70 lesion (in whom a greater propor-
tion of events arose from recurrent disease at orig-
inally treated culprit lesions). This observation is
consistent with the imaging findings of increased
atherosclerosis and greater necrotic core in patients
with PB70 lesions (as well as in the PB70 lesions
themselves). Interestingly, the presence of only 1
PB70 lesion conferred a similar increased risk of
adverse events as when multiple PB70 lesions per
patient were present. Moreover, a high proportion
of clinical events at follow-up attributed to imaged
nonculprit lesions were caused by PB70 lesions,
consistent with their increased lesion-specific risk.
However, even when the 25 events arising from
imaged PB70 lesions were excluded, the rate of
Figure 2. MACE per Lesion During Follow-Up
Major adverse cardiac events (MACE) per lesion during a median fo
burden.nonculprit MACE remained numerically greater in
patients with compared to those without PB70
lesions, reflecting the increased patient-level risk.
Moreover, while the concomitant presence of
smaller MLA and greater necrotic core no doubt
contributed to the increased lesion-specific risk in
PB70 lesions, the percent PB was found to be the
strongest multivariable predictor of future lesion-
specific MACE (11).
As previously reported, most of the events at
follow-up were rehospitalizations for unstable or
progressive angina (11). Because fractional flow
reserve was not routinely performed during the
PROSPECT study, it is unknown what propor-
tion of PB70 lesions were ischemia-producing at
the time of initial imaging. However, 50% of
the PB70 lesions had an MLA 4.0 mm2, and
only 4.9% had an MLA 2.4 mm2. In this regard
nitial studies that associated a MLA 4.0 mm2
with ischemia (20,21) have come into question
given poor specificity of this measure. Recently,
Kang et al. reported that an MLA 2.4 mm2 has
igh accuracy for excluding angiographically in-
ermediate lesions with ischemic potential (22).
iven the greater presence of necrotic core in
B70 lesions, it is possible that they may be more
ikely to rapidly progress and rupture (23), re-
ardless of their ischemic potential at the time of
he initial imaging.
Noninvasive assessment using coronary calcium
coring and computed tomographic coronary an-
iography has shown a consistent association with
-up of 3.4 years according to the maximum degree of plaquellow
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S84overall disease burden and the risk of future cardio-
vascular events (4,5,24,25). These studies generally
measured disease burden by calcium scores (4,5) or
by the number of epicardial vessels with obstructive
lesions (24,25). The present study extends this
evidence by correlating clinical outcomes with de-
tailed measurements of overall coronary atheroscle-
rosis and plaque characteristics using IVUS analysis.
On the basis of these data, patients with substantial
residual atherosclerosis found on invasive imaging
after PCI should be considered at particularly high
risk for future events (especially when PB70 lesions
are present).
Study limitations. As post-hoc analysis, the results
f the present study should be considered explor-
tory and hypothesis-generating. A requirement for
tudy enrollment was the ability to perform IVUS
maging of the proximal 6 to 8 cm of all major
picardial vessels. Thus, patients with chronically
ccluded or diffusely diseased vessels were not
ncluded in this analysis. Angiographic follow-up
as performed only in patients with clinical events
ecessitating repeat angiography; thus, data regard-
ng progression of atherosclerotic disease were lim-
ted to these patients. Approximately one-half of
onculprit lesion–related MACE arose from lesions
istal in the coronary tree that were not imaged by
VUS-VH. Most of these lesions supply a smaller
mount of myocardium, however, and thus are
ikely to be of less clinical relevance than the lesions
uccessfully imaged. Nonetheless, IVUS-VH data
ere available at baseline from only approximately
ne-half of the nonculprit lesions from which un-
nticipated future events arose, and the findings
rom the present report therefore apply principally
o the proximal and mid coronary tree. The accu-
acy of coregistering the angiographic and IVUSet al. 2009 focused updates: ACC/ py–Thrombolysis inimitations given angiographic foreshortening, non-
onstant IVUS pullback speed, and different image
lice widths. Nonetheless, the technique as applied
n the PROSPECT study appears to provide clin-
cal utility. Finally, while the nature of the under-
ying atherosclerosis in patients with PB70 lesions is
onsistent with the role of systemic inflammation in
he pathogenesis and progression of coronary artery
isease, the present study did not specifically assess
easures of inflammation, such as serum biomark-
rs or local evidence of macrophage or T-cell
nfiltration.
C O N C L U S I O N S
A large amount of untreated coronary atheroscle-
rosis remains in patients following successful PCI
for high-risk ACS. Untreated lesions are character-
ized by a large overall plaque volume, significant
amounts of necrotic core and dense calcium, and a
high proportion of fibroatheromas. Patients with at
least 1 PB70 lesion are at especially high risk of
future MACE arising not only from these severe
lesions, but also at sites of lesser PB, possibly
reflecting the systemic inflammatory nature of
ACS. The high rate of future events in these
patients was evident despite close clinical monitor-
ing and adherence to evidence-based medical ther-
apies. Further studies are warranted to determine
the appropriate management strategies for patients
with severe residual atherosclerosis after successful
PCI in ACS.
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